DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aloprim (Allopurinol) - Summary

 
 



ALOPRIM SUMMARY

ALOPRIM (allopurinol sodium) for Injection is the brand name for allopurinol, a xanthine oxidase inhibitor. ALOPRIM (allopurinol sodium) for Injection is a sterile solution for intravenous infusion only.

ALOPRIM (allopurinol sodium) for Injection is indicated for the management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.


See all Aloprim indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Aloprim (Allopurinol)

Gout: data from Phase III studies of lesinurad in combination with allopurinol
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.11.19]
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...

Less than half of gout patients reach recommended treatment goal following treatment with allopurinol
Source: Gout News From Medical News Today [2013.10.31]
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout.

Gout drug may reduce risk of death
Source: Gout News From Medical News Today [2014.03.26]
In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout)...

more news >>

Published Studies Related to Aloprim (Allopurinol)

Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. [2011.08.16]
OBJECTIVES: The aim of this study was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and endothelial function in subjects with stable coronary artery disease (CAD). BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, prolongs the time to chest pain during exercise in angina. We sought to ascertain whether allopurinol also improves endothelial dysfunction in optimally treated CAD patients, because such an effect might be of value to reduce future cardiovascular mortality. The mechanism of the anti-ischemic effect of allopurinol could be related to its reducing xanthine oxidase-induced OS, and our second aim was to see whether allopurinol really does reduce vascular tissue OS in CAD patients... CONCLUSIONS: Our study demonstrates that, in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascular tissue OS and improves 3 different measures of vascular/endothelial dysfunction. The former effect on OS might underpin the anti-ischemic effect of allopurinol in CAD. Both effects (on OS and endothelial dysfunction) increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality in CAD, over and above existing optimum therapy. (Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina; ISRCTN15253766). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. [2011.07]
Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD.Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. [2011.07]
OBJECTIVE: This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1beta monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment... CONCLUSIONS: Single canakinumab doses >/=50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg.

Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. [2011.06]
OBJECTIVES: Endothelial dysfunction is a well known risk factor for atherosclerosis. Uric acid levels are associated with endothelial dysfunction and atherosclerosis even if in physiological range. Xanthine oxidase inhibition with allopurinol decreases uric acid levels and oxidative stress and improves endothelial function. We have investigated the effect of high-dose and long-term allopurinol therapy on endothelial function in diabetic normotensive patients... CONCLUSION: Long-term and high-dose allopurinol therapy significantly improved endothelial function in diabetic normotensive patients. In addition, allopurinol therapy contributes to the lower HbA1c levels.

Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. [2011.04]
CONCLUSIONS: Allopurinol does not produce additional antihypertensive effects in patients with treated arterial hypertension. Allopurinol increases aortic compliance independently of ACE-I or thiazide-based, antihypertensive therapy. However, this effect is significantly dependent on the initial PWV in the aorta and on SBP changes during allopurinol therapy.

more studies >>

Clinical Trials Related to Aloprim (Allopurinol)

Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode [Recruiting]
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo, as add-on to mood stabilizers and/or antipsychotic in the treatment of patients with bipolar disorder, in a manic episode.

Allopurinol Combination Study [Recruiting]
To compare the proportion of subjects whose serum urate (sUA) levels are < 6. 0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate hypouricemic response with standard doses of allopurinol.

A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient [Recruiting]
To know the blood level of allopurinol in chronic kidney disease (CKD) patient.

Allopurinol in Acute Coronary Syndrome [Recruiting]
Allopurinol is a drug commonly used to treat gout. However recent studies have shown it has the potential to help improve oxygen supply to heart muscle. In this study the Investigators aim to find out if allopurinol slows down the onset of angina symptoms, as seen by a doctor on a tracing of the heart (ECG- electrocardiogram), for patients who have been diagnosed with heart disease, when exercising on a treadmill. The Investigators are also are trying to figure out the best dose of allopurinol to use and to see how quickly it begins working. To do this the investigators will recruit patients with angina, exercise them on a treadmill after giving different doses of allopurinol and see if there is an improvement in their time to bring on angina symptoms and signs. Patients recruited to this trial will receive three different treatment regimes over a six week period. Each treatment regime will last for one week with a one week rest period between each regime. This will involve up to eleven visits to Ninewells Medical School, Dundee for testing.

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies [Recruiting]
This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of rasburicase is more effective in treating hematologic malignancies when given together with or without allopurinol

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Aloprim has an overall score of 8. The effectiveness score is 10 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
 

Aloprim review by 62 year old male patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   gout
Dosage & duration:   300 mg taken 1xper day for the period of 4 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   I would get painful swelling in my feet. I could not even stand the bed sheet to touch my feet. One time while on vacation I was swollen up to my knees. The medication makes my life easier. I don't have to worry that when I wake up I won't be able to walk around my house. I rarely have any slight indication that the gout is going to be a problem.
Side effects:   None that I have noticed. I used to have painful swelling regularly and now I don't.
Comments:   I just take one pill per day. I take it every day as a prevention. I think it controls the uric acid my body produces too much of that causes the fluid retention and the swelling.

See all Aloprim reviews / ratings >>

Page last updated: 2014-11-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014